Negative Symptom and Cognitive Deficit Treatment Response in Schizophrenia
Edited by Richard S. E. Keefe, Ph.D., and Joseph P. McEvoy, M.D.
- 216 Pages
- Editorial Reviews
- ISBN 978-0-88048-785-6
- Item #8785
For the first time in a single volume, distinguished experts address the complex issues—issues rarely confronted in empirical studies of patients with schizophrenia—and controversial research surrounding the assessment of negative symptoms and cognitive deficits in patients with schizophrenia.
Despite recent advances in our understanding of schizophrenia, still notably absent is consensus in assessing negative symptom treatment response. What is the most effective assessment method—given the varying methodologies and contradictory results to date? What constitutes an adequate response? Which medication—none is specifically indicated and licensed for negative symptom treatment—yields the best results? What are the indications for use of this medication? Which instrument best measures negative symptom treatment response (eight rating scales are analyzed here)? Reaching consensus among clinicians and researchers alike is even more difficult because assessment is often thwarted by extrapyramidal side effects of medications, similarities to depressive symptoms, and secondary effects of psychotic experiences.
In addition to clarifying these pressing issues, Negative Symptom and Cognitive Deficit Treatment Response in Schizophrenia also discusses
- The importance of measuring the experience of emotion versus the more traditional objectively measured symptoms in patients with schizophrenia, and how deficits in emotional experience may resist treatment—even in treatment-responsive patients.
- The family as an often overlooked source of information about negative symptom improvement or worsening, and the impact of negative symptoms on patients’ relatives.
- How treatment affects social functioning and subjective experience of “quality of life,” and the importance of neurocognitive dysfunction in the social deficits of schizophrenia, which often persist despite significant amelioration of other symptoms.
- Specific guidelines for assessing neurocognitive treatment response. Cognitive enhancement is a major factor in improving the quality of patients’ lives.
- The latest research on the neurobiology of negative symptoms, including the role of various neurotransmitter systems and brain regions in mediating negative symptom pathology. Also discussed is single vs. multiple pathophysiological processes and single treatment modality vs. distinct treatments for different aspects of negative symptoms.
- How to distinguish “pure” negative symptoms from deficit symptoms (i.e., those that persist for at least 1 year and are not secondary to factors such as depression, medication side effects, anxiety, delusions, and hallucinations), and which treatment is indicated for each.
Highlighted by patient vignettes, this in-depth guide will be welcomed by all clinicians who treat patients with schizophrenia and want to know and document whether their interventions ameliorate negative symptoms and cognitive dysfunction, and by all researchers who study schizophrenia, particularly those interested in clinical issues and treatment studies.
- Chapter 1. Evaluating Negative Symptom Treatment Efficacy
- Chapter 2. Issues in the Assessment of Negative Symptom Treatment Response
- Chapter 3. Social Functioning and Its Relationship to Cognitive Deficits Over the Course of Schizophrenia
- Chapter 4. Evaluation of Negative Symptoms in Short-Term Pharmacological Trials
- Chapter 5. Negative Symptoms and the Assessment of Neurocognitive Treatment Response
- Chapter 6. Negative Symptoms and the Experience of Emotion
- Chapter 7. The Family Perspective in the Assessment of Negative Symptom Treatment Efficacy
- Chapter 8. Regulatory Aspects of Drug Treatment for Negative Symptoms
- Chapter 9. The Biology and Pathophysiology of Negative Symptoms
About the Authors
Richard S. E. Keefe, Ph.D., is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at Duke University Medical Center in Durham, North Carolina.
Joseph P. McEvoy, M.D., is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at Duke University Medical Center in Durham, North Carolina.
This book provides much information about one of the most important current issues in the treatment of schizophrenia and it covers both pharmaceutical and psychosocial aspects of treatment.—Peter E. Liddle, British Journal of Psychiatry, 1/1/2003
The development of effective treatments for negative symptoms and cognitive impairments remains the critical challenge facing schizophrenia therapeutics. This book provides the clinician with an accessible and comprehensive overview of the assessment issues, approaches, and tools that should enhance the everyday care of patients with schizophrenia.—Jim Gold, Ph.D., Maryland Psychiatric Research Center, University of Maryland, Baltimore, Baltimore, Maryland
This book comprehensively covers one of the most important topics in psychiatry. As a major cause of functional disability, the treatment of negative and cognitive symptoms is a matter of the highest priority. Assembling a collection of the most experienced researchers in the field, this book covers all of the important topics in a clearly written and thorough manner. The newest developments in research and theory are interspersed with informative clinical observations, leading to a highly readable collection of chapters of an optimal length.—Philip D. Harvey, Ph.D., Professor of Psychiatry, Mount Sinai School of Medicine, New York, New York